Clinical Trials on Multiple Mieloma in India

Total 63 results

Piramal Enterprises Limited

Completed

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

India
Amgen

Active, not recruiting

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma

India
Gleneagles Hospital
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma (dtZ)

Multiple Myeloma

Korea, Republic of, Singapore, India
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Johnson & Johnson Private Limited

Completed

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Multiple Myeloma

India
Novo Cellular Medicine Institute LLP

Unknown

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Multiple Sclerosis, Relapsing-Remitting

India, Trinidad and Tobago
Chaitanya Hospital, Pune

Unknown

Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)

Multiple Sclerosis

India
The Centre for Advanced Research & Development,...

Unknown

Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis (RFQMR)

Multiple Sclerosis

India
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
Sanofi

Completed

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (SAFE)

Relapsing Multiple Sclerosis

India
Marco J. Bruno
Boston Scientific Corporation

Recruiting

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries (PREVENT)

Cholangiopancreatography, Endoscopic Retrograde | Drug Resistance, Multiple, Bacterial

United States, India, Netherlands, Italy
Asian Institute of Gastroenterology, India

Recruiting

To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope (RDIH-01)

Hemostatic Disorder | POEMS Syndrome

India
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Janssen Research & Development, LLC

Completed

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma

United States, Australia, France, Spain, Israel, India, Romania, Korea, Republic of, Singapore, Russian Federation, Poland
AstraZeneca

Recruiting

Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule. (CREATE)

Lung Malignancy

Turkey, India, Indonesia
Centocor, Inc.

Withdrawn

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Belgium, Poland, Bulgaria, Turkey, Ukraine, Australia, Korea, Republic of, New Zealand, Czech Republic, United Kingdom, Netherlands, India
Celgene

Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

Multiple Myeloma

India, Philippines, France, Portugal, Poland, South Africa, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Serbia, Slovakia, United Kingdom
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
GlaxoSmithKline

Recruiting

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14)

Multiple Myeloma

United States, Italy, Poland, Spain, Taiwan, Brazil, Greece, Ireland, Mexico, Canada, Korea, Republic of, Germany, France, Australia, United Kingdom, Argentina, India, Thailand, Switzerland
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Korea, Republic of, Israel, Germany, Italy, Czechia, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Hyaline Fibromatosis Syndrome (BioHFS) (BioHFS)

Skin and Connective Tissue Diseases | Hyaline Membrane Disease | Hyalinosis | Juvenile Hyaline Fibromatosis | Fibromatosis Hyalinica Multiplex Juvenilis

Germany, Sri Lanka, India
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Argentina, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Biogen
Alkermes, Inc.

Completed

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Relapsing Remitting Multiple Sclerosis

United States, Germany, Poland
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (EXCHANGE)

Multiple Sclerosis | Relapsing Multiple Sclerosis | Advancing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Biogen
AbbVie

Terminated

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Novartis Pharmaceuticals

Completed

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (PREFERMS)

Relapsing Remitting Multiple Sclerosis

United States, Puerto Rico
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) (BioGM1/BioGM2)

Seizures | Mental Retardation | Hepato-splenomegaly | Dysostosis Multiplex

Egypt, Germany, India, Sri Lanka
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Multiple Sclerosis (MS)

United States, Belgium, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Spain, Argentina, France, Israel, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania and more
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Hoffmann-La Roche

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance 2)

Relapsing Multiple Sclerosis

United States, Korea, Republic of, India, Brazil, Poland, Canada, Bulgaria, United Kingdom, France, Greece, Italy, Russian Federation, Turkey, Mexico, Austria, Denmark, Guatemala
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

Relapsing Multiple Sclerosis

United States, Canada, China, Spain, Italy, France, Slovenia, Japan, Turkey, Argentina, Estonia, Greece, Mexico, Poland, Sweden, Croatia, South Africa, Brazil, Slovakia, Bulgaria, Romania, India, Portugal, United Kingdom, Puerto Rico
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Relapsing Multiple Sclerosis

United States, Belarus, Brazil, Bulgaria, Canada, France, Germany, Greece, India, Italy, Latvia, Lithuania, Malaysia, Moldova, Republic of, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia and more
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (GEMINI 2)

Relapsing Multiple Sclerosis

United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Korea, Republic of, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, Spai... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)

Relapsing Multiple Sclerosis

Belgium, Italy, United States, Croatia, Spain, Netherlands, Switzerland, Thailand, Israel, Czechia, Estonia, Poland, France, Bulgaria, Russian Federation, Germany, Turkey, Slovakia, Australia, Denmark, Greece, Argentina, India, Hungary, United Kingdom and more

Clinical Trials on Multiple Mieloma in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations